Literature DB >> 7093101

Labetalol in general practice: a review.

J A Kane.   

Abstract

1 The results of the treatment of 8573 hypertensive patients with labetalol in general practice, for periods between 1 month and 5 yr, are reviewed. 2 The data reviewed were obtained from the published literature together with our own published (Kane et al., 1976; Kane et al., 1979) and more recent (unpublished) work. 3 Between 60% and 80% of severe (diastolic blood pressure greater than 120 mmHg) and previously uncontrolled hypertensives responded satisfactorily to the drug, as did up to 88% of mild to moderate hypertensives. 4 The anti-hypertensive effect of labetalol was not dependent on the frequency of administration, twice and three times daily treatment regimes being equally effective. 5 The withdrawal rate attributable to side-effects was between 6% and 13%. Tiredness, dizziness, headache and upper gastro-intestinal symptoms were the four principal side-effects, but they were usually transient when labetalol treatment was continued. 6 No drug interactions or adverse haematological or biochemical changes were seen.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093101      PMCID: PMC1401839          DOI: 10.1111/j.1365-2125.1982.tb01890.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension.

Authors:  R G Wilcox
Journal:  Br Med J       Date:  1978-08-05

2.  Labetalol in the treatment of hypertension in general practice.

Authors:  P Forsell; J O'Sullivan; N Carson
Journal:  Aust Fam Physician       Date:  1979-11

3.  A new alpha and beta receptor antagonist in general practice.

Authors:  W S Manderson
Journal:  Practitioner       Date:  1979-01

4.  Experience with labetalol in essential hypertension.

Authors:  J Tuomilehto; A Nissinen; J Elo
Journal:  Curr Med Res Opin       Date:  1980       Impact factor: 2.580

5.  Labetalol in inadequately controlled hypertensive patients. A twice-daily oral regimen.

Authors:  A P Douglas-Jones
Journal:  Practitioner       Date:  1980-08

6.  A long-term study of labetalol in general practice.

Authors:  J Kane; I Gregg; M D Stephens
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

7.  Labetalol ('trandate') in hypertension: a multicentre study in general practice.

Authors:  G Gomez; L A Phillips
Journal:  Curr Med Res Opin       Date:  1980       Impact factor: 2.580

8.  Labetalol in the difficult hypertensive patient in general practice.

Authors:  C Harris
Journal:  Curr Med Res Opin       Date:  1978       Impact factor: 2.580

  8 in total
  5 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

2.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 3.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 4.  Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence.

Authors:  Janet B McGill
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 5.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.